Insider · CIK 0002041173
David Canner
director
Files at IKT (Inhibikase Therapeutics, Inc.). First filing -, latest -.
Track record
Not enough history
Fewer than three past buys with six months of prices.
Median 6-month excess
-
after past buys, n = 0
Hit rate
-
past buys that beat the index over 6 months
Open-market trades
0 / 0
$0 bought, $0 sold
Signals
This insider’s open-market buys and sells, scored.
No scored open-market trades yet.
Transactions
Every row this insider has filed, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jun 30, 2025 | IKT Inhibikase Therapeutics, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +108,176 | $0.00 | $0 | 108,176 | Jul 2, 2025 |
| Feb 14, 2025 | IKT Inhibikase Therapeutics, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +22,640 | $0.00 | $0 | 22,640 | Feb 19, 2025 |
| Feb 14, 2025 | IKT Inhibikase Therapeutics, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +116,585 | $0.00 | $0 | 116,585 | Feb 19, 2025 |
| Oct 21, 2024 | IKT Inhibikase Therapeutics, Inc. | AGrant or award Stock Option (right to buy)derivative | +60,000 | $0.00 | $0 | 60,000 | Oct 23, 2024 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.